Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 21

1.

Capsaicin 8% patch repeat treatment plus standard of care (SOC) versus SOC alone in painful diabetic peripheral neuropathy: a randomised, 52-week, open-label, safety study.

Vinik AI, Perrot S, Vinik EJ, Pazdera L, Jacobs H, Stoker M, Long SK, Snijder RJ, van der Stoep M, Ortega E, Katz N.

BMC Neurol. 2016 Dec 6;16(1):251.

2.

Conversion to eslicarbazepine acetate monotherapy: A pooled analysis of 2 phase III studies.

Sperling MR, French J, Jacobson MP, Pazdera L, Gough M, Cheng H, Grinnell T, Blum D; Study 045 and 046 Investigators.

Neurology. 2016 Mar 22;86(12):1095-102. doi: 10.1212/WNL.0000000000002497. Epub 2016 Feb 24.

3.

Prolonged-release oxycodone-naloxone for treatment of severe pain in patients with Parkinson's disease (PANDA): a double-blind, randomised, placebo-controlled trial.

Trenkwalder C, Chaudhuri KR, Martinez-Martin P, Rascol O, Ehret R, Vališ M, Sátori M, Krygowska-Wajs A, Marti MJ, Reimer K, Oksche A, Lomax M, DeCesare J, Hopp M; PANDA study group.

Lancet Neurol. 2015 Dec;14(12):1161-70. doi: 10.1016/S1474-4422(15)00243-4. Epub 2015 Oct 19.

PMID:
26494524
4.

Painful lumbosacral plexopathy: a case report.

Ehler E, Vyšata O, Včelák R, Pazdera L.

Medicine (Baltimore). 2015 May;94(17):e766. doi: 10.1097/MD.0000000000000766.

5.

Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a historical-control phase III study.

Jacobson MP, Pazdera L, Bhatia P, Grinnell T, Cheng H, Blum D; study 046 team.

BMC Neurol. 2015 Mar 28;15:46. doi: 10.1186/s12883-015-0305-5.

6.

Age-related changes in EEG coherence.

Vysata O, Kukal J, Prochazka A, Pazdera L, Simko J, Valis M.

Neurol Neurochir Pol. 2014 Jan-Feb;48(1):35-8. doi: 10.1016/j.pjnns.2013.09.001. Epub 2014 Jan 23.

PMID:
24636768
7.

Pick and Alzheimer diseases: a rare comorbidity presenting as corticobasal syndrome.

Rusina R, Pazdera L, Kulišťák P, Vyšata O, Matěj R.

Cogn Behav Neurol. 2013 Dec;26(4):189-94. doi: 10.1097/WNN.0000000000000011.

PMID:
24378604
8.

Change in the characteristics of EEG color noise in Alzheimer's disease.

Vysata O, Procházka A, Mares J, Rusina R, Pazdera L, Valis M, Kukal J.

Clin EEG Neurosci. 2014 Jul;45(3):147-51.

PMID:
24131619
9.

Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis.

Radue EW, O'Connor P, Polman CH, Hohlfeld R, Calabresi P, Selmaj K, Mueller-Lenke N, Agoropoulou C, Holdbrook F, de Vera A, Zhang-Auberson L, Francis G, Burtin P, Kappos L; FTY720 Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) Study Group.

Arch Neurol. 2012 Oct;69(10):1259-69.

PMID:
22751847
10.

Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study.

Devonshire V, Havrdova E, Radue EW, O'Connor P, Zhang-Auberson L, Agoropoulou C, Häring DA, Francis G, Kappos L; FREEDOMS study group.

Lancet Neurol. 2012 May;11(5):420-8. doi: 10.1016/S1474-4422(12)70056-X. Epub 2012 Apr 10. Erratum in: Lancet Neurol. 2012 Aug;11(8):658.

PMID:
22494956
11.

Symptoms and signs of posterior circulation ischemia in the new England medical center posterior circulation registry.

Searls DE, Pazdera L, Korbel E, Vysata O, Caplan LR.

Arch Neurol. 2012 Mar;69(3):346-51. doi: 10.1001/archneurol.2011.2083. Epub 2011 Nov 14.

PMID:
22083796
12.

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P; FREEDOMS Study Group.

N Engl J Med. 2010 Feb 4;362(5):387-401. doi: 10.1056/NEJMoa0909494. Epub 2010 Jan 20.

13.

[Somatosensoric prosthesis for the blind].

Vysata O, Procházka A, Kukal J, Becvárovský P, Pazdera L.

Cesk Slov Oftalmol. 2008 Sep;64(5):207-10. Czech.

PMID:
18988476
14.

New England Medical Center Posterior Circulation Stroke Registry II. Vascular Lesions.

Caplan L, Wityk R, Pazdera L, Chang HM, Pessin M, Dewitt L.

J Clin Neurol. 2005 Apr;1(1):31-49. doi: 10.3988/jcn.2005.1.1.31. Epub 2005 Apr 30.

15.

New England medical center posterior circulation stroke registry: I. Methods, data base, distribution of brain lesions, stroke mechanisms, and outcomes.

Caplan L, Chung CS, Wityk R, Glass T, Tapia J, Pazdera L, Chang HM, Dashe J, Chaves C, Vemmos K, Leary M, Dewitt L, Pessin M.

J Clin Neurol. 2005 Apr;1(1):14-30. doi: 10.3988/jcn.2005.1.1.14. Epub 2005 Apr 30.

16.

New England Medical Center Posterior Circulation registry.

Caplan LR, Wityk RJ, Glass TA, Tapia J, Pazdera L, Chang HM, Teal P, Dashe JF, Chaves CJ, Breen JC, Vemmos K, Amarenco P, Tettenborn B, Leary M, Estol C, Dewitt LD, Pessin MS.

Ann Neurol. 2004 Sep;56(3):389-98.

PMID:
15349866
17.

Expanding the phenotypic spectrum of the CACNA1A gene T666M mutation: a description of 5 families with familial hemiplegic migraine.

Kors EE, Haan J, Giffin NJ, Pazdera L, Schnittger C, Lennox GG, Terwindt GM, Vermeulen FL, Van den Maagdenberg AM, Frants RR, Ferrari MD.

Arch Neurol. 2003 May;60(5):684-8.

PMID:
12756131
18.

Outcome at 30 days in the New England Medical Center Posterior Circulation Registry.

Glass TA, Hennessey PM, Pazdera L, Chang HM, Wityk RJ, Dewitt LD, Pessin MS, Caplan LR.

Arch Neurol. 2002 Mar;59(3):369-76.

PMID:
11890839
19.

Primary orthostatic tremor with prominent muscle hypertrophy.

Hanna M, Mills K, Pazdera L, Newsom-Davis J.

Neurology. 1997 Sep;49(3):872-4.

PMID:
9305357
20.

[Enamel lesions caused by evaporation of inorganic acids as described in the medical literature].

Pazdera L.

Cesk Stomatol. 1967 Jan;67(1):71-3. Review. Czech. No abstract available.

PMID:
5335955

Supplemental Content

Loading ...
Support Center